Trial Profile

Phase 2/3 Trial of Autologous Hybrid TREG/Th2 Cell (RAPA-501) Therapy for Amyotrophic Lateral Sclerosis

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RAPA 501 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions
Sponsors Rapa Therapeutics

Most Recent Events

08 Nov 2024 Planned End Date changed from 1 Jul 2025 to 1 Jun 2027.
08 Nov 2024 Planned primary completion date changed from 1 Jul 2025 to 1 Jul 2026.
08 Nov 2024 Planned initiation date changed from 1 Sep 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com